Impacting Global Health Delivery Through Advocacy: The Case of Losartan

Glob Heart. 2019 Mar;14(1):95-96. doi: 10.1016/j.gheart.2018.11.001. Epub 2018 Dec 21.

Authors

David J Heller¹, Sandeep P Kishore²

Affiliations

¹ Arnhold Institute for Global Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: [email protected].
² Arnhold Institute for Global Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PMID: 30584029
DOI: 10.1016/j.gheart.2018.11.001

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Angiotensin II Type 1 Receptor Blockers / therapeutic use
Cardiovascular Diseases / drug therapy*
Cardiovascular Diseases / epidemiology
Global Health
Humans
Losartan / therapeutic use*
Morbidity / trends
Survival Rate / trends

Substances

Angiotensin II Type 1 Receptor Blockers
Losartan

Grants and funding

R21 TW010452/TW/FIC NIH HHS/United States